Dutton Associates Announces Investment Opinion: Sinovac Bio

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » RSS Yahoo BIOTECH
Reply to topic
Dutton Associates Announces Investment Opinion: Sinovac Bio
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Tue Jun 10, 2008 10:26 am Reply with quote


ROSEVILLE, Calif.----Dutton Associates updates its coverage of Sinovac Biotech maintaining a Strong Speculative Buy rating and a price target of $5.31. The 11-page report by Dutton senior analyst Stanley Ng is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

Read more...
View user's profileSend private message
Dutton Associates Announces Investment Opinion: Sinovac Bio
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » RSS Yahoo BIOTECH
 Reply to topic  
Forum Map
Site Map